Association between cystatin C and diabetic retinopathy among type 2 diabetic patients in China: a Meta-analysis

Nan Yang\textsuperscript{1}, Yun-Fei Lu\textsuperscript{1}, Xiao Yang\textsuperscript{1}, Kui Jiang\textsuperscript{1}, Ai-Min Sang\textsuperscript{2}, Hui-Qun Wu\textsuperscript{1}

\textsuperscript{1}Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China
\textsuperscript{2}Department of Ophthalmology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China

Co-first authors: Nan Yang and Yun-Fei Lu

Correspondence to: Hui-Qun Wu. Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, Jiangsu Province, China. wuhuiqun@ntu.edu.cn

Received: 2021-03-08        Accepted: 2021-05-14

Abstract

● AIM: To explore the correlation between cystatin C (Cys-C) and diabetic retinopathy (DR) in those patients with type 2 diabetes mellitus (DM) in China.

● METHODS: Articles were collected from China National Knowledge Infrastructure (CNKI), Wanfang, VIP, PubMed, EMBASE, Cochrane Library, Clinical Trials.gov, and Google Scholar. Quality and risk of bias within included studies was assessed using the Newcastle-Ottawa scale (NOS). Heterogeneity was determined by using Cochran’s Q-test and Higgins I\textsuperscript{2} statistics. Mean differences (MDs) and 95% confidence intervals (CIs) of Cys-C within the diabetes without retinopathy (DWR) and DR, DWR and non-proliferative diabetic retinopathy (NPDR), NPDR and proliferative diabetic retinopathy (PDR) were collected by using random-effects model because of high heterogeneity. Meta-analysis was conducted based on 23 articles of 2331 DR including NPDR and PDR patients and 2023 DWR patients through Review Manager 5.3. Subgroup analyses were also performed according to DM duration, body mass index (BMI), total cholesterol (TC), total triglycerides (TG), low-density lipoprotein C (LDL-C), and high-density lipoprotein C (HDL-C), sample origins and methods. Publication bias was assessed by the funnel plot.

● RESULTS: Cys-C level in DR patients was increased compared with that of DWR (total MD: 0.69, 95%CI: 0.41 to 0.97, Z=4.79, P<0.01). Besides, the synthesized results of the studies showed the similar findings in the DWR vs NPDR group (total MD: 0.29, 95%CI 0.20 to 0.39, Z=6.02, P<0.01) and the NPDR vs PDR group (total MD: 0.63, 95%CI 0.43 to 0.82, Z=6.33, P<0.01). Heterogeneity of most of the subgroup analyses was still obvious (I\textsuperscript{2}≥50%, P<0.1). Forest plots of different subgroups indicated that there was a slight increase of Cys-C during the period between DWR and DR, DWR and NPDR, NPDR and PDR. Funnel plot showed that there was no significant publication bias.

● CONCLUSION: The elevated Cys-C is closely related with DR and probably plays a critical role in its progression.

● KEYWORDS: diabetic retinopathy, cystatin C; Meta-analysis

DOI:10.18240/ijo.2021.09.21

INTRODUCTION

Diabetes mellitus (DM) totally affected nearly 463 million people over the world in 2019 and this number is estimated to reach 578 million by 2030\textsuperscript{[1]}. Diabetic retinopathy (DR) is a serious microvascular complication deriving from DM\textsuperscript{[2]}. As the prevalence of DM continues to rise, incidences of DR which threatens the vision are projected to increase to 191 million by 2030. DR remains the major cause of blindness in adults worldwide\textsuperscript{[3-4]}. According to the clinical study, DR is divided into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is the earliest stage of DR and can develop into PDR without effective treatment\textsuperscript{[5]}. Various factors such as hypertension, obesity, hyperlipidemia and hyperglycemia cause DR exacerbation\textsuperscript{[6]}. Several mechanisms including altered endothelial cell junctions, inflammatory processes and central retinal venous congestion were proposed for its pathogenesis\textsuperscript{[7]}. Around 40% of patients with type 2 diabetes already have been diagnosed with retinopathy and another 20% will develop this disease in next 6y\textsuperscript{[8]}. Because of the high incidence, more diagnostic schemes are urgently needed.

Cystatin C (Cys-C) belongs to the type 2 cystatin gene family on chromosome 20\textsuperscript{[9]}. Almost every organ of the body can express Cys-C. Due to its high concentration in biologic fluids, Cys-C is an important extracellular inhibitor of cysteine proteases\textsuperscript{[10-12]}. It is a non-glycosylated protein that plays...
pleiotropic roles in human vascular patho-physiology[13]. Clinically, the index of Cys-C is used as a diagnostic parameter to record glomerular filtration rate (GFR) due to its easy detection and lower molecular weight. Previously, researchers have done Meta-analyses to prove that serum Cys-C is a predictor of diabetic nephropathy in diabetic patients[14-15]. However, the fluctuation of Cys-C level may have more important clinical value than a mere parameter of kidney function[16]. National Health and Nutrition Examination Survey (NHANES) found that Cys-C could be a better predictor for DR compared to creatinine, related to shared pathogenic pathways between retinopathy and Cys-C[17-18]. One previous study demonstrated that higher serum Cys-C levels were positively associated with the frequency of DR, chronic heart disease and stroke in type 2 DM patients with normal renal function or mild renal impairment[19]. Furthermore, such Meta-analysis on the correlation between Cys-C and DR has not been reported yet. Considering both nephropathy and retinopathy are microvascular complications of DM, we carried out the Meta-analysis to explore the clinical value of serum Cys-C for DR.

MATERIALS AND METHODS

Search Strategy and Selection Criteria We performed a computerized search of PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), VIP and Wanfang to identify potentially relevant articles published to August 2020. We also searched Google Scholar and Clinical Trials for unpublished studies. The search terms and strategies for PubMed were “diabetic retinopathy”, “diabetic retinopathies”, “retinopathies, diabetic”, “retinopathy, diabetic”, “Cystatin C”, “Cys-C”, “post-gamma-globulin”, “post gamma globulin”, “neuroendocrine basic polypeptide”, “basic polypeptide, neuroendocrine”, “Cystatin 3”, “gamma-trace” and “gamma trace”. Two authors (Yang N and Lu YF) reviewed the list of articles. Two researchers (Yang N and Yang X) who read the full text of all studies determined the suitability for inclusion based on pre-specified inclusion criteria. The inclusion criteria included: case-control study; individuals with type 2 DM; the exact mean and standard deviation of Cys-C in serum and other sufficient data were provided. There was no limitation on age and no language or publishing date restrictions. If papers we collected are abstracts, letters, editorials, expert opinion, reviews, observational studies, or case reports, they would be excluded. In addition, overlapped or duplicate data, nonhuman research and insufficient data are also our exclusion criteria.

Data Extraction and Quality Assessment Two researchers (Yang N and Lu YF) participated in extracting data from the included studies. Disagreements about extracting data were solved through communication and discussion with a third reviewer (Yang X). Information such as first author’s name, year of publication, country, Cys-C detection method, sample number of participants, sex, mean age, body mass index (BMI), HbA1c, Cys-C, total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) was extracted precisely. If included literature represented outliers such as very large or very small data, researchers would eliminate the unusual data. Quality assessment of each included study was performed according to the Newcastle-Ottawa Scale (NOS). Studies with a score less than 5 indicated a high risk of bias.

Statistical Analysis and Subgroup Analyses We performed statistical analyses by applying Review Manager 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) provided by the Cochrane Collaboration by imputing the mean and standard deviation (SD) we recorded from included studies. The mean difference (MD) and 95% confidence interval (CI) were calculated, and $P<0.05$ was considered statistically significant. To adjust the possible heterogeneity among included studies, we divided samples into different subgroups as shown in Figure 1. We set the 10y as a cutting-off point for DM duration subgroup analysis. The subgroup of normal or abnormal TC, TG, HDL-C, and LDL-C according to Chinese Guidelines for Prevention and Treatment of Dyslipidemia in Adults (2016 Revision)[20] were analyzed.

Assessment of Heterogeneity and Publication Bias Heterogeneity will be assessed by Cochran’s Q-test and Higgins $I^2$ statistics. $I^2 \geq 50\%$ or $P<0.1$ indicated that there was a statistical heterogeneity, random effect model (REM) was applied to analyze the data. Funnel plots were used to evaluate the publication bias by the RevMan. If the funnel plots were roughly symmetrical, no publication bias was present.

RESULTS

A workflow diagram of eliminating and including literatures was presented in Figure 2. A total of 195 articles were identified after removing duplicates and among them four were excluded due to comments and animal experiments. Next, 146 articles were further excluded after reading the abstract of the remaining articles for inconsistencies in research contents or measures and 13 were excluded after reading the full text because proper outcomes did not occur. Finally, eight articles appearing inconsistent outcomes and one articles appearing the same outcomes were further excluded. The remaining 23 articles were selected for the Meta-analysis.

Characteristics of the Included Studies The main characteristics of the included studies were summarized in Table 1. The 23 included studies[21-43] covered 2331 DR (NPDR or PDR) patients and 2023 diabetic without retinopathy (DWR) patients. DR patients were divided into NPDR and PDR in 12 studies. Among these 23 studies, 21 investigated serum Cys-C
levels and the other two investigated plasma Cys-C levels. The patients in 23 studies were all type 2 DM patients from China. Clinical characteristics like age, gender, DM duration, BMI, HbA1c, Cys-C, levels of TC, TG, HDL-C, LDL-C, and available renal function of DR patients were recorded. Eight research reported parameters related to renal function. Two articles provided data of GFR, five articles considered serum creatinine concentration (Scr) and one reported blood urea nitrogen (BUN) of samples. Among them, renal functions of patients in four studies\cite{19,26,30,38} were within normal range. Levels of other four groups or the DWR, DR subgroups were just a little away from standard. Blood sample origins including serum or plasma and experimental methods such as turbidimetric inhibition immune assay (TIIA) and enzyme linked immunosorbent assay (ELISA) were also recorded. Most patients were middle-aged or elderly and their age ranged from fifty to sixty. The overall duration of the disease varied from approximately 2 to 15y and most fluctuated within ten years. Most patients with DWR and DR (NPDR or PDR) showed BMI>24 kg/m\(^2\). Blood lipid parameters such as TC, TG, and LDL-C saw a slight to moderate increase between control groups and experiment groups. Eight studies were rated as a total score of 6, thirteen studies as a score of 7 and two studies as a score of 8, none of them indicated a high risk of bias.

**Meta-analysis of Overall Cys-C Levels in the DWR, NPDR, and PDR group** The forest plot of included eleven studies with 1813 participants showed the difference of Cys-C levels between the overall DR and DWR group (Figure 3). The heterogeneity was high \((P<0.1, \hat{I}^2>50\%)\). The result revealed that there was an increasing level of Cys-C in patients with DR (total MD: 0.69, 95%CI: 0.41 to 0.97, \(Z=4.79, P<0.01\)). Among the 23 studies, another 12 articles classified DR into
<table>
<thead>
<tr>
<th>Author, year</th>
<th>Method</th>
<th>Sample</th>
<th>NOS</th>
<th>DWR (NPDR/PDR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen 2015</td>
<td>THA</td>
<td>Serum</td>
<td>7</td>
<td>TC 5.69±0.93 mmol/L, HDL-C 1.25±0.41 mmol/L, LDL-C 2.57±0.57 mmol/L</td>
</tr>
<tr>
<td>Chen 2019</td>
<td>THA</td>
<td>Blood</td>
<td>6</td>
<td>n=229 (M/F 140/89), age 55.12±7.96y, duration 5.92±3.26y, Cys-C 1.31±0.52 mmol/L</td>
</tr>
<tr>
<td>Lai 2015</td>
<td>THA</td>
<td>Plasma</td>
<td>7</td>
<td>n=60 (MF 140/89), age 55.7±6.8y, BMI 21.12±2.05, Cys-C 0.72±0.18 mmol/L, TG 4.02±0.85 mmol/L</td>
</tr>
<tr>
<td>Guo 2020</td>
<td>THA</td>
<td>Serum</td>
<td>7</td>
<td>n=52 (MF 19/62), age 56.07±10.8y, BMI 24.95±2.97, HbAlc 7.8%±1.27%, Cys-C 0.60±0.19 mmol/L, TC 4.7±0.96 mmol/L, TG 1.72±0.44 mmol/L, HDL-C 1.48±0.55 mmol/L, LDL-C 2.54±0.68 mmol/L</td>
</tr>
<tr>
<td>Wang 2017</td>
<td>THA</td>
<td>Serum</td>
<td>7</td>
<td>n=53 (MF 31/22), age 57.13±6.3y, BMI 24.72±3.29, HbAlc 10.21%±1.56%, Cys-C 0.91±0.09 mmol/L, TC 5.12±0.75 mmol/L, HDL-C 1.21±0.08 mmol/L, LDL-C 2.76±0.63 mmol/L</td>
</tr>
<tr>
<td>Wu 2014</td>
<td>THA</td>
<td>Serum</td>
<td>6</td>
<td>n=92 (MF 52/40), age 56.37±8.07y, BMI 24.38±1.93, HbAlc 9.11%±2.90%, Cys-C 0.91±0.67 mmol/L, TC 5.83±1.32 mmol/L, HDL-C 1.13±0.62 mmol/L, LDL-C 3.36±0.01 mmol/L, GFR 9.87±18.57 mL/min, Scr 57.84±11.57 μmol/L</td>
</tr>
<tr>
<td>Wu 2015</td>
<td>THA</td>
<td>Serum</td>
<td>6</td>
<td>n=57, age 56.41±6.9y, duration 8.0±0.6y, BMI 23.6±1.9, Cys-C 0.85±0.25 mmol/L, TC 5.28±1.32 mmol/L, HDL-C 0.96±0.24 mmol/L, LDL-C 2.88±0.42 mmol/L, GFR 74±6.84 mL/min</td>
</tr>
<tr>
<td>Wu 2018</td>
<td>THA</td>
<td>Serum</td>
<td>6</td>
<td>n=43 (MF 21/22), age 64.1y, duration 11.7y, HbAlc 9.28±1.02%, Cys-C 0.98±0.12 mmol/L</td>
</tr>
<tr>
<td>Yan 2018</td>
<td>THA</td>
<td>Serum</td>
<td>6</td>
<td>n=80 (MF 38/42), age 54.0±15.2y, BMI 26.5±6.12, HbAlc 8.59%±1.94%, Cys-C 0.86±0.11 mmol/L, TC 4.27±0.99 mmol/L, HDL-C 1.10±0.26 mmol/L, LDL-C 2.56±0.76 mmol/L, Scr 66.4±11.43 μmol/L</td>
</tr>
<tr>
<td>Zhang 2011</td>
<td>THA</td>
<td>Plasma</td>
<td>7</td>
<td>n=4.0 (MF 26/34), age 52.8y, duration 5.6y, BMI 23.2±0.7, HbAlc 7.4%±1.2%, Cys-C 1.35±0.54 mmol/L</td>
</tr>
<tr>
<td>Zhao 2013</td>
<td>-</td>
<td>Serum</td>
<td>6</td>
<td>n=3.0 (MF 57/52), age 57.2±11.4y, duration 10.1±6.2y, BMI 22.2±4.59, HbAlc 6.4±0.5%, Cys-C 0.98±0.23 mmol/L, TC 4.12±0.99 mmol/L, HDL-C 1.35±0.34 mmol/L, LDL-C 2.81±0.57 mmol/L, Scr 71.89±10.21 μmol/L</td>
</tr>
<tr>
<td>Author, year</td>
<td>Method</td>
<td>Sample</td>
<td>NOS</td>
<td>DWR (NPDR/PDR)</td>
</tr>
<tr>
<td>Bao 2018</td>
<td>-</td>
<td>Serum</td>
<td>7</td>
<td>n=3.0 (MF 13/17), age 52.01±5.44y, duration 8.1±5.5y, Cys-C 0.84±0.23 mmol/L</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>ELISA</td>
<td></td>
<td></td>
<td>n=45 (MF 22/23), age 64.5±6.9y, duration 0.5±5y, Cys-C 0.88±0.67 mmol/L</td>
</tr>
<tr>
<td>Chen 2017</td>
<td>THA</td>
<td>Serum</td>
<td>6</td>
<td>n=3.87 (MF 19/29), age 55.21±12.0y, duration 6.83±0.7y, BMI 25.33±4.03, HbAlc 8.94%±1.35%, Cys-C 1.42±0.33 mmol/L, TC 4.01±1.33 mmol/L, TG 2.05±0.52 mmol/L, HDL-C 1.35±0.34 mmol/L, LDL-C 2.81±0.57 mmol/L, Scr 71.89±10.21 μmol/L</td>
</tr>
<tr>
<td>Chen 2017</td>
<td>ELISA</td>
<td>Serum</td>
<td>7</td>
<td>n=100 (MF 60/40), age 64.5±6.9y, duration 0.5±5y, Cys-C 0.88±0.67 mmol/L</td>
</tr>
<tr>
<td>Chen 2017</td>
<td>ELISA</td>
<td>Serum</td>
<td>7</td>
<td>n=100 (MF 60/40), age 64.5±6.9y, duration 0.5±5y, Cys-C 0.88±0.67 mmol/L</td>
</tr>
</tbody>
</table>

Note: DWR (NPDR/PDR) denotes the levels of various biomarkers in different studies.
<table>
<thead>
<tr>
<th>Author, year</th>
<th>Method</th>
<th>Sample</th>
<th>NOS</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cui 2019</td>
<td>ELISA</td>
<td>Serum</td>
<td>7</td>
<td>n=42 (MF 23/19), age 57.98±8.62y, duration 7.17±2.76y, BMI 25.98±5.92, HbA1c 8.11%±1.54%, Cys-C 0.72±0.31 mmol/L, TC 5.32±0.80 mmol/L, TG 1.92±0.99 mmol/L, LDL-C 2.97±0.80 mmol/L.</td>
</tr>
<tr>
<td>Han 2019</td>
<td>—</td>
<td>Serum</td>
<td>7</td>
<td>n=52 (MF 30/22), age 56.42±8.90y, duration 6.04±2.61y, BMI 23.42±3.41, HbA1c 6.22%±0.70%, Cys-C 1.08±0.68 mmol/L, TC 4.80±0.82 mmol/L, TG 2.18±0.92 mmol/L, LDL-C 3.4±0.42 mmol/L, HDL-C 0.65±0.30 mmol/L.</td>
</tr>
<tr>
<td>Jin 2019</td>
<td>TIIA</td>
<td>Serum</td>
<td>8</td>
<td>n=49 (MF 24/25), age 70.03±8.2y, duration 5.3±3.2y, HbA1c 6.7%±0.8%, Cys-C 0.95±0.38 mmol/L.</td>
</tr>
<tr>
<td>Li 2015</td>
<td>TIIA</td>
<td>Serum</td>
<td>7</td>
<td>n=50 (MF 27/23), age 61.9±5.4y, duration 5.9±1.7y, BMI 26.4±3.0, HbA1c 7.2%±0.9%, Cys-C 1.08±0.68 mmol/L, TC 4.80±0.82 mmol/L, TG 2.18±0.92 mmol/L, LDL-C 3.4±0.42 mmol/L, HDL-C 0.65±0.30 mmol/L.</td>
</tr>
<tr>
<td>Wang 2018</td>
<td>Latex</td>
<td>Serum</td>
<td>8</td>
<td>n=25 (MF 64/61), age 56.8±5.4y, duration 2.9±1.1y, BMI 25.1±2.4, HbA1c 7.2%±1.8%, Cys-C 0.94±0.13 mmol/L, TC 4.92±1.03 mmol/L, TG 1.81±0.76 mmol/L, HDL-C 1.46±0.65 mmol/L, LDL-C 2.53±1.02 mmol/L.</td>
</tr>
<tr>
<td>Wang 2019</td>
<td>TIIA</td>
<td>Serum</td>
<td>8</td>
<td>n=28 (MF 14/14), age 53.2±9.9y, duration 6.36±5.44y, BMI 25.52±4.00, HbA1c 7.59%±1.59%, Cys-C 0.84±0.20 mmol/L, BUN 5.81±2.38 mmol/L.</td>
</tr>
<tr>
<td>Wei 2017</td>
<td>ELISA</td>
<td>Serum</td>
<td>6</td>
<td>n=28, age 45.4±5.9y, duration 6.54±5.86y, Cys-C 1.35±0.18 mmol/L.</td>
</tr>
<tr>
<td>Yang 2016</td>
<td>TIIA</td>
<td>Serum</td>
<td>6</td>
<td>n=4, age 53.4±8.7y, duration 12.5±4.3, Cys-C 1.64±0.21 mmol/L.</td>
</tr>
</tbody>
</table>

NOS: The Newcastle-Ottawa Scale; DWR: Diabetic without retinopathy; DR: Diabetic retinopathy; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic retinopathy; TIIA: Turbidimetric inhibition immune assay; ELISA: Enzyme linked immunosorbent assay; BMI: Body mass index; Cys-C: Cystatin C; TC: Total cholesterol; TG: Triglycerides; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; GFR: Glomerular filtration rate; Scr: Serum creatinine concentration; BUN: Blood urea nitrogen.
NPDR and PDR. Mean difference of Cys-C between DWR and NPDR was presented in Figure 4. The forest plot indicated higher Cys-C level in the NPDR than that of the DWR (total MD: 0.29, 95%CI: 0.20 to 0.39, \(P<0.01\)). Meanwhile, the similar effect was observed in the PDR vs NPDR group (total MD: 0.63, 95%CI 0.43 to 0.82, \(P=0.07\); Figure 5).

**Subgroup Analysis Results** The results comparison between DWR and DR was presented in Figure 6. The heterogeneity of most of the subgroup analyses was still obvious (\(I^2\geq50\%), \(P<0.01\)). The Cys-C level of the DR group was noticeably higher than that of the DWR group except BMI\(\leq24\ \text{kg/m}^2\) subgroup (subtotal MD: 1.03, 95%CI -0.50 to 2.56, \(P=0.07\); Figure 7). Two exceptions showed the same result because both included the same articles. In subgroup analyses between DWR and NPDR, NPDR and PDR, the difference of the level of Cys-C between control group and experiment group presented the same trend as the comparison between DWR and DR. As Figure 7 showed, different subgroups in DWR and NPDR attained huge decrease in heterogeneity to some extent such as BMI>24 kg/m\(^2\) (\(P=0.16\), \(I^2=39\%). Particularly, ELISA (\(P=0.54\), \(I^2=0\) displayed no heterogeneity. Forest plots of different subgroups indicated that there was a slight increase of Cys-C during the period between DWR and NPDR. In another subgroup analyses of NPDR and PDR in Figure 8, heterogeneity of the majority remained the similarly high level as DWR and DR (\(I^2\geq50\%), \(P<0.01\)). One obvious decline was only observed in the subgroup of LDL-C<3.4 mmol/L (\(P=0.07\), \(I^2=69\%\)). Likewise, a small increase could be seen in the process from NPDR to PDR.
Publication Bias Analysis

We performed a funnel plot analysis to investigate the potential publication bias among included articles. In addition to data of DR-DWR from included 11 articles without classifying DR into NPDR and PDR, we input data of NPDR-DWR and PDR-DWR from the other 12 research into DR-DWR. The result showed that the distribution of studies was almost symmetrical, therefore no significant publication bias was found (Figure 9).

DISCUSSION

Cystatin C is widely used as a biomarker of kidney function for its relatively easy detection and lower molecular weight to measure GFR. Cystatin C is removed from the blood by glomerular filtration, whose concentration will increase in serum due to failed kidney function. Previous Meta-analysis compared the diagnostic accuracy of Cys-C with creatinine[14]. Based on this physical property, another Meta analysis proved the predicting value of Cys-C in diabetic nephropathy[15]. In our study, we analyzed the role of Cys-C in DR. To prove its relationship with DR, we firstly analyzed 11 articles dealing with the comparison between DWR and DR. After data from these articles was input in Revman, forest plot showed that there was an increase in the level of Cys-C in DR in contrast with DWR. Further results showed that there was an obvious increase in levels of Cys-C from DWR to NPDR and NPDR to PDR. That is, as the DR disease progresses, the amount of Cys-C shows an upward trend, suggesting the Cys-C is strongly associated to DR severity. We carried out the subgroup analysis, the Cys-C...
level of the DR group was significantly higher than that of the DWR group. Forest plots of different subgroups indicated that there was a slight increase during the period between DWR and NPDR.

Heterogeneity of subgroup BMI > 24 kg/m² (P = 0.16, I² = 39%) and subgroup ELISA (P = 0.54, I² = 0) becomes depleted. Increase could be apparent in the process from NPDR to PDR. DR is a serious microvascular complication deriving from DM. Some biochemical mechanisms have been proposed to explain the pathogenesis of retinopathy through effects on cellular metabolism, signal pathways. Implicated pathways such as oxidative stress, protein kinase C activation, inflammation, and vascular endothelial growth factor (VEGF) have been proved to relate with the process of DR. VEGF is a principal mediator of DR, capable of inducing changes in NPDR and PDR. Elucidation of VEGF-induced cellular and molecular mechanisms involved in DR has provided the foundation of developing novel therapeutic approaches to preventing ocular complications. As an extracellular inhibitor of cysteine protease, Cys-C involves in this biochemical mechanism. Previous study covering the neurovascular units (NVUs) in Parkinson’s disease demonstrates that Cys-C induced angiogenesis via regulating the level of secreted VEGF protein in the NVUs. Cys-C induced VEGF attenuated 6-OHDA-lesioned PC12 cell degeneration by regulating p-PKC-α/p-ERK1/2-Nurr1 signaling and inducing enhanced autophagy. In the NVUs, VEGF in the conditioned media of 6-OHDA-lesioned PC12 cells over-expressing Cys-C markedly increased angiogenesis. Besides, blockage of autophagy by 3-methyladenine (3-MA) in the Cys-C-over-expressing PC12 cells significantly decreased VEGF expression and VEGF-mediated angiogenesis. It’s proved that over-expression of Cys-C increased VEGF expression. In addition, one research about systemic lupus erythematosus (SLE) demonstrated that the increasing degrees of Cys-C are positively correlated with the level of VEGF in vivo. From the view of neuron, several studies of animals and humans have confirmed that retinal cells are damaged by diabetes dysfunction of Müller cells. Müller glia plays an important role in neovascularization, vascular leakage, and vascular lesion in diabetic retinas. VEGF signaling is closely related with Müller glia viability and neuroprotection in diabetic/hypoxic retinas. As the conclusion that the level of Cys-C is positively correlated with the degree of VEGF talked before, we infer that Cys-C plays a vital role in the viability of Müller glia. Inflammation also plays an important role in DR development. Inflammatory cytokines, such as C-reactive protein and tumor necrosis factor alpha have been suggested to contribute to the progression of DR. Cys-C level was found to be correlated significantly to biomarkers reflecting inflammation, independent of renal function. It demonstrated that a partial correlation between Cys-C and multiple biomarkers of inflammation including CRP, interleukin-6, tumor necrosis factor-α soluble receptor I and factor VIII. These researches help prove the effect of Cys-C on inflammation.
Despite the findings we achieved, the present Meta-analysis had several limitations. First, heterogeneity in our Meta-analysis may limit the generalization of the pooled result and the source of heterogeneity could not be discerned by a subgroup analysis. Subgroup analysis was also conducted to explore the heterogeneity. The heterogeneity of most of the subgroup analyses was still obvious in the comparison between DWR and DR, NPDR and PDR. It is worth mentioning that BMI > 24 kg/m² and ELISA displayed lower heterogeneity in subgroup analysis between DWR and NPDR. Second, the number of studies in this Meta-analysis is relatively small. Third, some included studies had missed description such as method of detecting the level of Cys-C. Finally, all samples included in our analysis were all from China, lack of coherence from other countries.

In conclusion, this Meta-analysis verifies correlation between increased Cys-C levels and DR in Chinese type 2 DM patients. Large sample size prospective study is in need to confirm the findings in the future.

ACKNOWLEDGEMENTS

Foundations: Supported by the National Key R&D Program of China (No.2018YFC1314900; No.2018YFC1314902); National Natural Science Foundation of China (No.81971708); Science and Technology Project of Nantong City (No. MS12020037); Excellent Key Teachers in the “Qing Lan Project” of Jiangsu Colleges and Universities and “226 Project” of Nantong; Postgraduate Research & Practice Innovation Program of Jiangsu Province (No.KYCX20_2836); Jiangsu Students’ Platform for Innovation and Entrepreneurship Training Program (No.2020103040185E).

Conflicts of Interest: Yang N, None; Lu YF, None; Yang X, None; Jiang K, None; Sang AM, None; Wu HQ, None.

REFERENCES


Cystatin C and diabetic retinopathy

